

|   |  |                                       |                               |
|---|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449<br>(Modified)  | U.S. Department of Commerce<br>Patent and Trademark Office | Attorney's Docket No.<br>14875-134US1 | Application No.<br>10/510,971 |
| <b>Information Disclosure Statement<br/>by Applicant</b><br>(Use several sheets if necessary) |  | Applicant<br>Tetsuo Kojima            |                               |
|   |  | Filing Date<br>October 12, 2004       | Group Art Unit                |
| [37 CFR §1.98(b)]   |  |                                       |                               |

| U.S. Patent Documents |           |                 |                  |          |       |                            |
|-----------------------|-----------|-----------------|------------------|----------|-------|----------------------------|
| Examiner Initial      | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass                   |
|                       | AA        |                 |                  |          |       | Filing Date If Appropriate |

| Foreign Patent Documents or Published Foreign Patent Applications |           |                 |                  |                          |       |             |
|---|-----------|-----------------|------------------|--------------------------|-------|-------------|
| Examiner Initial  | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass    |
|   | AB        |                 |                  |                          |       | TRANSLATION |
|   | AC        |                 |                  |                          |       |             |

| Other Documents (include Author, Title, Date, and Place of Publication) |           |  |  |  |  |  |
|---|-----------|--|--|--|--|--|
| Examiner Initial  | Desig. ID | Document   |  |  |  |  |
| /LB/  | AD        | McGuinness BT et al., "Phage display repertoire for selection of large number of bispecific antibody fragments", <i>Nature Biotechnology</i> , Vol. 14(9), pages 1149-1154 (1996).   |  |  |  |  |
|   | AE        | DeNardo D.G. et al., "Anti-HLA-DR/anti-DOTA diabody construction in modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy", <i>Cancer Biotherapy &amp; Radiopharmaceuticals</i> , Vol. 16(6), pages 525-535 (2001). |  |  |  |  |
|   | AF        | Andris-Widhopf J. et al., "Methods for the generation of chicken monoclonal antibody fragments by phage display", <i>Journal of Immunological Methods</i> , Vol. 242, pages 159-181 (2000).  |  |  |  |  |
|   | AG        | Turner D.J. et al., "Importance of the linker in expression of single-chain Fv antibody fragments: optimization of peptide sequence using phage display technology", <i>Journal of Immunological Methods</i> , Vol. 205, pages 43-54 (1997).         |  |  |  |  |
|   | AH        | Tang Y. et al., "Selection of linkers for a catalytic single-chain antibody using phage display technology", <i>The Journal of Biological Chemistry</i> , Vol. 271(26), pages 15682-15686 (1996).  |  |  |  |  |
| ↓   | AI        | Holliger P. et al., "Diabodies', small bivalent and bispecific antibody fragments", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pages 6444-6448 (1993).   |  |  |  |  |

|   |                               |
|---|-------------------------------|
| Examiner Signature<br>/Lynn Bristol/  | Date Considered<br>04/11/2008 |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                               |